AbbVie Inc. (NYSE:ABBV) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of AbbVie Inc. (NYSE:ABBV) have received a consensus rating of “Moderate Buy” from the twenty-six analysts that are covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $276.6364.

Several equities analysts recently weighed in on the company. Cantor Fitzgerald increased their target price on AbbVie from $265.00 to $285.00 and gave the stock an “overweight” rating in a research report on Monday, August 3rd. BNP Paribas Exane upped their price objective on shares of AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Finally, Canaccord Genuity Group raised their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Qulipta migraine expansion: AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. The treatment met its primary and secondary endpoints, potentially opening a new indication and supporting intermittent use rather than continuous daily dosing. This could expand Qulipta’s commercial opportunity and reinforce AbbVie’s position in migraine care. AbbVie’s migraine treatment meets late-stage study goal
• Positive Sentiment: Higher HSBC valuation: HSBC raised its price target for AbbVie to $315 from $300 while maintaining a Buy rating, signaling continued confidence in the company’s growth outlook and product pipeline. HSBC adjusts price target on AbbVie
• Positive Sentiment: Dividend maintained: AbbVie declared a quarterly cash dividend of $1.73 per share, payable Nov. 16 to shareholders of record Oct. 15. The unchanged payout supports the stock’s income appeal and reflects continued shareholder-return capacity. AbbVie declares quarterly dividend
• Neutral Sentiment: Pipeline and portfolio developments: Coverage highlighted the growth of Skyrizi and Rinvoq, the planned $10.9 billion Apogee Therapeutics acquisition, an ADARx collaboration and updated real-world data from an eye-implant study. These initiatives may diversify future growth, but their financial impact remains dependent on execution, approvals and clinical outcomes.
• Negative Sentiment: Regulatory setback: The FDA issued a Complete Response Letter for trenibotE, AbbVie’s fast-acting neurotoxin candidate. The action may delay the product’s launch and add uncertainty around the aesthetics pipeline. FDA issues Complete Response Letter for AbbVie’s trenibotE
• Negative Sentiment: Concentration and valuation concerns: Analysts continue to monitor AbbVie’s reliance on Skyrizi and the long-term effects of Humira’s patent-related decline. With the stock trading at a relatively elevated earnings multiple, execution risks and slower-than-expected diversification could limit further upside.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Litman Gregory Wealth Management LLC acquired a new position in shares of AbbVie in the 4th quarter valued at about $28,000. Imprint Wealth LLC increased its position in AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Burk Holdings LLC purchased a new position in AbbVie in the second quarter valued at approximately $30,000. Legacy Wealth Managment LLC ID raised its holdings in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after buying an additional 73 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new position in AbbVie during the fourth quarter valued at approximately $31,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

ABBV stock opened at $255.00 on Friday. The company has a 50 day moving average price of $254.54 and a two-hundred day moving average price of $230.76. The stock has a market capitalization of $450.52 billion, a P/E ratio of 72.03, a PEG ratio of 1.13 and a beta of 0.29. AbbVie has a one year low of $190.75 and a one year high of $267.47.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the prior year, the company posted $2.97 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts forecast that AbbVie will post 14.05 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.